Sat, Jul 12, 2014, 5:40 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

  • left2rightdoor left2rightdoor Jan 7, 2013 11:44 AM Flag

    Hepatitis treatments and how to improve after treatment failures

    Many of these articles show need for new treatment modalities.
    Articles: Hepatitis for January 7, 2013
    Ranked, sorted, and summarized by MDLinx editors from the latest literature
    7 new articles from 75 contributor journals scanned today (see the list)
    Efficacy and Safety of Pegylated Interferon Alfa–2a or Alfa–2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in Children and Adolescents: A Systematic Review and Meta–analysis Evidence Based Medicine
    Clinical Infectious Diseases
    Update on the treatment of patients with non–genotype 1 HCV infection Review Article Evidence Based Medicine
    Clinical Infectious Diseases
    Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures Full Text
    World Journal of Gastroenterology
    The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil Full Text
    BMC Infectious Diseases
    Efficacy of pegylated interferon alpha–2a AND alpha–2b in patients with genotype 1 chronic Hepatitis C: a meta–analysis Full Text Evidence Based Medicine
    BMC Infectious Diseases

    Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion
    Current management and perspectives for HCV recurrence after liver transplantation
    Liver International

12.18+0.38(+3.22%)Jul 11 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.